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The efficacy of Direct Antiviral Agents (DAAs) is limited
by the presence of Resistant associated virus mutations
(RAVs) resulting in amino-acid substitutions within the
targeted proteins which affect viral sensitivity to these
compounds. Six major position mutations in the NS3
HCV Protease (36, 54, 155, 156, 168, and 170), fifteen in
the NS5B polymerase (96, 282, 316, 365, 414, 419, 423,
448, 482, 494, 495, 496, 499, 554, 559) and five in the
NS5 A region (28, 30, 31, 58 and 93) have now been
reported in vitro or in vivo associated with different levels
of resistance.
The HCV NS3,NS5A, Pol (NNI) mutations occurred
quickly (less than 15 days) and longer for Nucleosides
Inhibitors in monotherapy and the genetic barrier can be
overcome by combination with Pegylated-Interferon
+Ribavirine in quadruple therapy. There is a long term
persistence of HCV NS3 Protease mutations after the end
of therapy and it is important to stop the NS3 protease
inhibitor early in patients with ongoing replication to
avoid the selection of resistant variants with increased fit-
ness and a higher potential of long-term survival. Issues
on HCV archived mutations are not solved. Virological
failure was more likely in patients with genotype 1a infec-
tion than 1b and was associated with the presence of resis-
tant variants. Furthermore, the time taken for resistant
HCV variant populations to return to WT is longer for
patients with genotype 1a versus genotype 1b.
Selection of resistant variants that, in turn, could pro-
duce cross-resistance to whole class of drugs with overlap-
ping resistance profiles Combinations of Protease
Inhibitors with other class of antiviral with separate modes
of action & non-overlapping resistance profile is prefer-
able. Additionally, Ribavirine prevents viral breakthrough
in combination with Pegylated-Interferon and DAAs and
the effect of ribavirin important seems limit the DAA
resistance.
The resistance profiling does remain a challenge for
the next generation of protease, NS5A, non nucleoside
inhibitors and probably for nucleoside inhibitors; thus,
the lessons from HIV infection and the first clinical
proof of IFN-free regimen treatment indicate that com-
binations of drugs with different mechanisms of action
will be an attractive strategy for hepatitis C.
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